Early Disease-Modifying Treatments for Presymptomatic Multiple Sclerosis
Zeydan B, Azevedo C, Makhani N, Cohen M, Tutuncu M, Thouvenot E, Siva A, Okuda D, Kantarci O, Lebrun-Frenay C. Early Disease-Modifying Treatments for Presymptomatic Multiple Sclerosis. CNS Drugs 2024, 1-11. PMID: 39285136, DOI: 10.1007/s40263-024-01117-9.Peer-Reviewed Original ResearchRadiologically isolated syndromeRisk factorsLaboratory biomarkersMultiple sclerosisDisease-modifying treatmentsSpinal cordGadolinium-enhancing lesionsEfficacy of disease-modifying treatmentsRandomized clinical trialsIncrease diagnostic accuracyLack of clinical guidelinesSymptomatic MSNeurofilament-light chainCSF abnormalitiesPresymptomatic individualsAdverse eventsMale sexMS criteriaClinical eventsDiagnostic accuracyClinical trialsDisease outcomeClinical guidelinesYounger ageLesionsThe diagnostic value of the central vein sign in radiologically isolated syndrome
Landes‐Chateau C, Levraut M, Okuda D, Themelin A, Cohen M, Kantarci O, Siva A, Pelletier D, Mondot L, Lebrun‐Frenay C, Lebrun‐Frenay C, Kantarci O, Siva A, Pelletier D, Azevedo C, Makhani N, Okuda D. The diagnostic value of the central vein sign in radiologically isolated syndrome. Annals Of Clinical And Translational Neurology 2024, 11: 662-672. PMID: 38186317, PMCID: PMC10963291, DOI: 10.1002/acn3.51986.Peer-Reviewed Original ResearchConceptsRadiologically isolated syndromeCentral vein signCVS+ lesionsNon-MSMultiple sclerosisControl group of sex-RIS diagnosisAge-matched subjectsDetectable preclinical phaseProportion of lesionsWhite matter lesionsGroup of sex-Effective imaging biomarkerMagnetic resonance imagingDiagnostic performanceDiagnostic accuracyDiagnostic valueLesion criteriaImaging biomarkersLesionsResonance imagingLesion-specificAbsolute numberControl groupROC comparisons